Affimed (NASDAQ:AFMD) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Affimed (NASDAQ:AFMD) in a report released on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Several other equities analysts have also commented on the stock. Leerink Partnrs lowered shares of Affimed from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. HC Wainwright downgraded shares of Affimed from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 14th. Leerink Partners reissued a “market perform” rating and set a $0.39 target price (down previously from $5.00) on shares of Affimed in a research report on Tuesday, May 13th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $0.10 price objective (down previously from $11.00) on shares of Affimed in a research report on Tuesday, May 13th. Finally, Cantor Fitzgerald cut shares of Affimed from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $7.90.

Affimed Stock Up 227.8%

Shares of AFMD stock opened at $0.28 on Monday. The company has a 50 day simple moving average of $0.73 and a two-hundred day simple moving average of $1.39. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a 12 month low of $0.07 and a 12 month high of $8.95.

Institutional Investors Weigh In On Affimed

A hedge fund recently raised its stake in Affimed stock. Intellectus Partners LLC increased its stake in shares of Affimed (NASDAQ:AFMD) by 34.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,414 shares of the biopharmaceutical company’s stock after purchasing an additional 32,053 shares during the quarter. Intellectus Partners LLC owned approximately 0.79% of Affimed worth $150,000 as of its most recent filing with the Securities and Exchange Commission. 30.82% of the stock is owned by institutional investors and hedge funds.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.